The course of platinum-based chemotherapy is associated with the risk of hematological complications during poly(ADP-ribose) polymerase (PARP) inhibitor therapy in patients with ovarian cancer.
- DOI
- 10.1007/s43440-026-00888-w
- Published
- 2026 Aug 12
- Container
- Pharmacological reports : PR
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s43440-026-00888-w,
title = {The course of platinum-based chemotherapy is associated with the risk of hematological complications during poly(ADP-ribose) polymerase (PARP) inhibitor therapy in patients with ovarian cancer.},
author = {Miedziarek C and Gładych-Macioszek A and Potograbski M and Kapłon A and Nowak-Markwitz E and Zaborowski MP},
year = {2026},
journal = {Pharmacological reports : PR},
doi = {10.1007/s43440-026-00888-w},
url = {https://doi.org/10.1007/s43440-026-00888-w}
}RIS
TY - JOUR TI - The course of platinum-based chemotherapy is associated with the risk of hematological complications during poly(ADP-ribose) polymerase (PARP) inhibitor therapy in patients with ovarian cancer. AU - Miedziarek C AU - Gładych-Macioszek A AU - Potograbski M AU - Kapłon A AU - Nowak-Markwitz E AU - Zaborowski MP PY - 2026 JO - Pharmacological reports : PR DO - 10.1007/s43440-026-00888-w UR - https://doi.org/10.1007/s43440-026-00888-w ER -
APA
C, M., A, G., M, P., A, K., E, N., & MP, Z. (2026). The course of platinum-based chemotherapy is associated with the risk of hematological complications during poly(ADP-ribose) polymerase (PARP) inhibitor therapy in patients with ovarian cancer.. Pharmacological reports : PR. https://doi.org/10.1007/s43440-026-00888-w
Source records
- pubmed · retrieved 2026-09-26T03:25:08.614Z